US2022113311A1PendingUtilityA1

Methods of Detecting and Treating a Tumor Expressing PT346 PDK1

72
Assignee: WISTAR INSTPriority: Aug 7, 2016Filed: Dec 23, 2021Published: Apr 14, 2022
Est. expiryAug 7, 2036(~10 yrs left)· nominal 20-yr term from priority
Inventors:Dario C. Altieri
G01N 33/57557G01N 33/575A61K 45/06A61K 31/5383A61K 31/496A61K 31/167G01N 2333/91205A61K 31/19C07K 16/28G01N 33/573C12N 15/1137G01N 2333/91215A61K 31/7088A61K 31/385A61K 31/444A61P 35/00C12N 2320/31A61K 31/519A61K 31/4439G01N 2440/14C12N 2310/14A61K 31/20G01N 33/57407
72
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Therapeutic treatments of a tumor expressing pT346 PDK1, including glioma expressing pT346 PDK1, are disclosed.

Claims

exact text as granted — not AI-modified
1 .- 10 . (canceled) 
     
     
         11 : A method of detecting the presence of a hypoxic glioma tumor in a human subject comprising
 isolating a biological sample from the human subject and   detecting the presence of pT346 PDK1 in the biological sample,   wherein the presence of pT346 PDK1 indicates the presence of a hypoxic glioma tumor.   
     
     
         12 : The method according to  claim 11 , wherein the pT346 PDK1 level in the biological sample is compared to a level of pT346 PDK1 in normoxic cells. 
     
     
         13 . The method according to  claim 11 , wherein the biological sample is a tissue biopsy or blood sample. 
     
     
         14 . The method according to  claim 11 , wherein the detecting comprises contacting the biological sample with an anti-pT346 antibody and detecting binding between pT346 PDK1 and the antibody. 
     
     
         15 . The method according to  claim 11 , wherein a higher level of pT346 PDK1 in the biological sample compared to a control indicates the presence or increase of the hypoxic glioma tumor. 
     
     
         16 . A composition for treating a tumor expressing pT346 PDK1, the composition comprising a therapeutically effective dose of a PDK1 inhibitor and/or a Protein Kinase B-beta (AKT) inhibitor.

Join the waitlist — get patent alerts

Track US2022113311A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.